163 related articles for article (PubMed ID: 38424386)
1. The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness.
Tassorelli C; Barbanti P; Finocchi C; Geppetti P; Kokturk P; Russo A; Sacco S; Cepparulo M;
Neurol Sci; 2024 May; 45(5):2353-2363. PubMed ID: 38424386
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
Ashina M; Mitsikostas DD; Amin FM; Kokturk P; Schankin CJ; Sahin G; Pozo-Rosich P; Dorman PJ; Nežádal T; Poole AC; Martins IP; Sumelahti ML; Ramirez Campos V; Ahn AH; Lyras L; Tassorelli C
Cephalalgia; 2023 Nov; 43(11):3331024231214987. PubMed ID: 37987641
[TBL] [Abstract][Full Text] [Related]
3. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine.
Ashina M; Amin FM; Kokturk P; Cohen JM; Konings M; Tassorelli C; Lyras L; Mitsikostas DD
Pain Manag; 2021 Nov; 11(6):647-654. PubMed ID: 34105377
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
Straube A; Broessner G; Gaul C; Hamann X; Hipp J; Kraya T; Neeb L
J Headache Pain; 2023 May; 24(1):59. PubMed ID: 37221478
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
7. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P; Egeo G; Aurilia C; d'Onofrio F; Albanese M; Cetta I; Di Fiore P; Zucco M; Filippi M; Bono F; Altamura C; Proietti S; Bonassi S; Vernieri F;
J Headache Pain; 2022 Apr; 23(1):46. PubMed ID: 35397503
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.
Driessen MT; Cohen JM; Patterson-Lomba O; Thompson SF; Seminerio M; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 Apr; 23(1):47. PubMed ID: 35410121
[TBL] [Abstract][Full Text] [Related]
10. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V; Russo A; Silvestro M; Tessitore A; De Icco R; Vaghi G; Sances G; Tassorelli C; Baraldi C; Castro FL; Guerzoni S; Prudenzano MP; Fallacara A; Gentile M; Ornello R; Onofri A; Burgalassi A; Chiarugi A; De Cesaris F; Granato A; Casalena A; De Tommaso M; Mampreso E; Merlo P; Coppola G; Battistini S; Rebecchi V; Rainero I; Sepe FN; Dalla Volta G; Sacco S; Geppetti P; Iannone LF;
CNS Drugs; 2023 Dec; 37(12):1069-1080. PubMed ID: 37999868
[TBL] [Abstract][Full Text] [Related]
12. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan.
Suzuki S; Suzuki K; Shiina T; Haruyama Y; Hirata K
Front Neurol; 2023; 14():1220285. PubMed ID: 37483436
[TBL] [Abstract][Full Text] [Related]
15. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
16. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
17. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
McAllister P; Cohen JM; Campos VR; Ning X; Janka L; Barash S
J Headache Pain; 2022 Aug; 23(1):112. PubMed ID: 36038833
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
Barbanti P; Egeo G; Proietti S; d'Onofrio F; Aurilia C; Finocchi C; Di Clemente L; Zucco M; Doretti A; Messina S; Autunno M; Ranieri A; Carnevale A; Colombo B; Filippi M; Tasillo M; Rinalduzzi S; Querzani P; Sette G; Forino L; Zoroddu F; Robotti M; Valenza A; Camarda C; Borrello L; Aguggia M; Viticchi G; Tomino C; Fiorentini G; Orlando B; Bonassi S; Torelli P;
Neurol Ther; 2024 Jun; 13(3):611-624. PubMed ID: 38451463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
